Form 4: Senseonics Director Stephen DeFalco Receives Equity Compensation Package

Senseonics Holdings, Inc. director Stephen P. DeFalco was granted 111,386 restricted stock units and 157,234 stock options as part of the company's non-employee director compensation policy.

Summary

• Stephen P. DeFalco, a Director of Senseonics Holdings, Inc. (SENS), received equity compensation on May 23, 2025.
• He was granted 111,386 Restricted Stock Units (RSUs) at a price of $0.00 per unit, with each RSU representing a contingent right to receive one share of common stock.
• He also received 157,234 stock options with an exercise price of $0.51 per share, which have an expiration date of May 22, 2035.
• Both the RSUs and stock options were granted pursuant to the Issuer's non-employee director compensation policy.
• The RSUs and options vest in full on the earlier of the one-year anniversary of the grant date or the next annual stockholders meeting, subject to continuous service.
• Following these transactions, Mr. DeFalco beneficially owns 2,023,347 shares of Common Stock and 157,234 stock options.

Sentiment

Score: 6

Explanation: The filing reports routine equity compensation for a non-employee director, which is a standard practice to align management and shareholder interests. While it involves potential future dilution, it's an expected part of corporate governance and compensation.

Positives

• The equity grants align the interests of Director Stephen P. DeFalco with those of the shareholders, as his compensation is tied to the company's stock performance.
• The grants are part of a pre-existing non-employee director compensation policy, indicating a structured approach to governance and incentive alignment.

Negatives

• The issuance of new RSUs and stock options, upon vesting and exercise, could lead to a minor dilutive effect on existing shareholders, although this is standard practice for equity compensation.

Risks

• Dilution Risk: The vesting and exercise of RSUs and stock options will increase the number of outstanding shares, potentially diluting the ownership percentage of existing shareholders.
• Performance Risk: The value of the granted equity compensation is directly tied to the future stock price of Senseonics Holdings, Inc., meaning the actual value realized by the director depends on the company's performance.
• Vesting Conditions: The vesting of the RSUs and options is subject to the director's continuous service, meaning the full benefit is contingent on his continued tenure.

Future Outlook

The vesting schedule for the RSUs and stock options, tied to the earlier of a one-year anniversary or the next annual stockholders meeting, indicates an expectation of continued service from Director Stephen P. DeFalco and a future increase in his direct beneficial ownership of common stock upon vesting and exercise.

Management Comments

• "Represents a restricted stock unit ('RSU') grant pursuant to the Issuer's non-employee director compensation policy (the 'Policy')."
• "Represents a stock option grant pursuant to the Policy."
• "The RSUs vest in full on the earlier of the one year anniversary of the date of grant or the next annual stockholders meeting, subject to the Reporting Person's continuous service through such vesting date."

Industry Context

The granting of equity compensation, such as Restricted Stock Units (RSUs) and stock options, to non-employee directors is a common and widely accepted practice across various industries, particularly in publicly traded companies. This approach is designed to align the interests of the board members with those of the shareholders, incentivizing long-term value creation and retention of key talent.

Comparison to Industry Standards

• Equity-Based Compensation: The use of RSUs and stock options for director compensation is a standard practice, comparable to compensation structures seen in other medical device or biotechnology companies of similar market capitalization. For instance, companies like Dexcom (DXCM) or Insulet Corporation (PODD), also in the diabetes management space, utilize equity grants to incentivize their non-employee directors.
• Vesting Schedules: The 'earlier of one-year anniversary or next annual stockholders meeting' vesting schedule is typical for annual director grants, ensuring continued engagement for at least the upcoming year. This is consistent with governance best practices aimed at retaining experienced board members.
• Exercise Price: The stock option exercise price of $0.51, which is common for options granted at fair market value on the grant date, is also standard.

Corporate Governance

Related Party Transactions

• The grant of 111,386 Restricted Stock Units and 157,234 stock options to Stephen P. DeFalco, a director of Senseonics Holdings, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: Potential minor dilution from the future vesting and exercise of RSUs and stock options, but also benefit from increased alignment of director interests with long-term company performance.
• Director (Stephen P. DeFalco): Receives equity-based compensation, incentivizing continued service and performance tied to the company's stock value.

Next Steps

• Vesting of the 111,386 Restricted Stock Units (RSUs) on the earlier of May 23, 2026, or the next annual stockholders meeting.
• Vesting of the 157,234 stock options on the earlier of May 23, 2026, or the next annual stockholders meeting.
• Potential exercise of stock options by Stephen P. DeFalco before the May 22, 2035 expiration date.

Key Dates

Keywords

Senseonics Holdings, SENS, Form 4, insider transaction, director compensation, restricted stock units, RSUs, stock options, equity grant, beneficial ownership, corporate governance